id,provider,model,object,created,choices,usage
gen-1728196335-VHfeBDazJptdhP563x35,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196335,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Improving physical and mental health in women with breast cancer undergoing anthracycline-based chemotherapy through wearable device-based aerobic exercise: a randomized controlled trial\n* **DOI**: 10.3389/fpubh.2024.1451101\n* **PMID**: 39363984\n* **PMCID**: PMC11446794\n* **Clinical Trial Registration**: ChiCTR2300073667 (https://www.chictr.org.cn/showproj.html?proj=200247)\n\n**Authors**\n\n* **Li H** (College of Physical Education, South-Central Minzu University, Wuhan, Hubei, China; Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China)\n* **Sang D** (Department of Breast Medicine, Sanhuan Cancer Hospital, Beijing, China)\n* **Gong L** (Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China)\n* **Wang B** (Discipline of Exercise and Sports Science, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia)\n* **Wang Y** (Department of Ultrasound, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China)\n* **Jia X** (Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China)\n* **Yu J** (Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China)\n* **Kong Z** (Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China)\n* **Liu H** (Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China)\n* **Zhang Y** (Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China)\n\n**Methods**\n\n* **Study Design**: Randomized controlled trial\n* **Participants**: 40 adult women with breast cancer undergoing anthracycline-based chemotherapy\n* **Intervention**: Wearable device-based aerobic exercise (50-90% HRmax) during chemotherapy\n* **Control Group**: Standard health education and oncology care without exercise intervention\n* **Outcome Measures**: Health-related physical fitness level, physical activity energy expenditure (PAEE), anxiety and depression scores, sleep quality, cancer-related fatigue, and overall quality of life (QoL)\n\n**Results**\n\n* **Primary Outcomes**:\n\t+ Relative VO2peak (p = 0.003)\n\t+ Handgrip strength (p < 0.001)\n\t+ PAEE (p < 0.001)\n\t+ Anxiety scores (p = 0.007)\n\t+ Depression scores (p = 0.028)\n\t+ Sleep quality (p = 0.010, p = 0.004, p = 0.007)\n\t+ Cancer-related fatigue (p < 0.001, p < 0.001)\n\t+ QoL (p < 0.001, p = 0.019, p < 0.001)\n* **Secondary Outcomes**:\n\t+ Gastrointestinal reactions (p = 0.028)\n\t+ Myelosuppressive symptoms (p < 0.001)\n\t+ Exercise-related adverse events (none reported)\n\t+ Exercise adherence (mean: 81.8%)\n\n**Conclusion**\n\n* Wearable device-based aerobic exercise during chemotherapy can be an effective adjunctive therapy to improve physical and mental health in breast cancer patients.', 'refusal': ''}}]","{'prompt_tokens': 966, 'completion_tokens': 767, 'total_tokens': 1733}"
gen-1728196383-No5bPUIwwd6IPTYZEaZE,Hyperbolic,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196383,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial\n* **DOI**: 10.31557/APJCP.2024.25.9.3039\n* **PMID**: 39342581\n* **Journal**: Asian Pacific Journal of Cancer Prevention\n* **Year**: 2024\n* **Volume**: 25\n* **Issue**: 9\n* **Pages**: 3039-3049\n\n**Trial Design**\n\n* **Type**: Randomised Clinical Trial\n* **Phase**: III\n* **Interventional**: Yes\n* **Concurrent**: Yes\n* **Open Label**: Yes\n* **Arm 1**: Palbociclib 125 mg/day orally for 3 weeks and 1 week rest, plus fulvestrant\n* **Arm 2**: Ribociclib at a dose of 600 mg, administered orally once daily for 3 weeks and 1 week rest, plus fulvestrant\n\n**Participant Information**\n\n* **Population**: Patients with pathologically proved ER+ HER2- metastatic breast cancer\n* **Inclusion Criteria**: Progressed on adjuvant hormonal or progressed on 1st line hormonal for metastatic disease\n* **Exclusion Criteria**: Not mentioned\n* **Number of Participants**: Not mentioned\n\n**Outcome Measures**\n\n* **Primary Outcome Measures**: Clinical Benefit Rate (CBR), Progression-Free Survival (PFS), Quality of Life (QOL), and toxicity profile\n* **Secondary Outcome Measures**: Not mentioned\n\n**Results**\n\n* **CBR**: 58.6% for both arms at 6 months and 13.8% in the palbociclib arm vs 17.2% in the ribociclib arm at 12 months (no statistically significant difference)\n* **Median PFS**: 13 months for the whole population\n* **COX Multivariate Analysis**: Postmenopausal patients had 2.85 times more likely to survive than premenopausal patients; patients with ECOG performance status 2 and 3 are 0.13 and 0.39 times less likely to survive compared to patients with PS 1; dose reduction increased the likelihood of survival 3.36 compared with no dose reduction\n* **Median PFS by Arm**: 13.67 months in the palbociclib arm and 12.69 months in the ribociclib arm (no statistically significant difference)\n* **QOL**: Statistically significant improvement in insomnia in both arms and constipation in the palbociclib arm alone; more deterioration in fatigue and financial difficulties in the palbociclib arm\n* **Toxicity Profile**: No statistically significant difference between the two arms\n\n**Conclusion**\n\n* Both Ribociclib and palbociclib have similar CBR, PFS, and toxicity profile.\n\n**Investigator Information**\n\n* **Principal Investigator**: Not mentioned\n* **Affiliation**: Mansoura University, Egypt\n\nNote: Some information is not provided in the text and has been left blank or mentioned as ""Not mentioned"".', 'refusal': ''}}]","{'prompt_tokens': 900, 'completion_tokens': 681, 'total_tokens': 1581}"
gen-1728196413-aY3XszQJtYrt6jru8zZp,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196413,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': ""Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)\n* **DOI**: 10.1186/s12911-024-02691-0\n* **PMID**: 39334347\n* **PMCID**: PMC11430334\n* **Trial Registration**: NCT04496739\n* **Journal**: BMC Medical Informatics and Decision Making\n* **Publication Date**: 2024 Sep 27\n\n**Study Design**\n\n* **Study Type**: Qualitative analysis of pre-implementation interviews\n* **Study Design**: Cluster randomized controlled trial (parent trial: MiCHOICE)\n\n**Objectives**\n\n* **Primary Objective**: To understand attitudes, beliefs, and barriers to chemoprevention among providers\n* **Secondary Objective**: To identify facilitators and potential solutions to improve informed choice about chemoprevention\n\n**Methodology**\n\n* **Participants**: 25 providers (18 physicians and 7 advanced practice providers)\n* **Data Collection**: Semi-structured interviews\n* **Data Analysis**: Qualitative analysis\n\n**Results**\n\n* **Themes**: Three themes emerged:\n\t1. Providers' confidence in chemoprevention and the utility of decision support tools\n\t2. Barriers to chemoprevention (time constraints, risk communication, patients' fear of side effects and anxiety)\n\t3. Need for early implementation of decision support tools\n\n**Conclusions**\n\n* **Main Finding**: Providers were interested in the early inclusion of decision aids in their chemoprevention discussion workflow\n* **Implication**: A multi-faceted intervention with a decision aid as one active component may be needed to overcome barriers to chemoprevention\n\n**Authors**\n\n* **First Author**: Michel AM\n* **Corresponding Author**: Am5314@cumc.columbia.edu\n\n**Institutions**\n\n* **Columbia University Irving Medical Center**\n* **SWOG Statistics and Data Management Center**\n* **Mayo Clinic**\n* **Miami Cancer Institute at Baptist Health South Florida**\n* **...** (see full list of institutions in the original text)\n\n**Conflict of Interest**\n\n* **Statement**: The authors declare no competing interests."", 'refusal': ''}}]","{'prompt_tokens': 1398, 'completion_tokens': 471, 'total_tokens': 1869}"
gen-1728196436-GLtRJqXxWmMKhGePm202,Together,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196436,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': ""Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Research on the comprehensive child life intervention program (CCLIP) for adjusting medical fear in children with central nervous system (CNS) cancers: a randomized controlled trial study protocol\n* **DOI**: 10.1186/s40359-024-02028-6\n* **PMCID**: PMC11438171\n* **PMID**: 39334285\n* **Trial Registration**: ChiCTR2400082622\n* **Registration Date**: April 2, 2024\n\n**Authors**\n\n* **Shen Y**: Department of Breast and Urological Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Wang M**: Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Wu XH**: Nursing Department, Children's Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China\n* **Du J**: Department of Head and Neck and Pediatric Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Wang YL**: Department of Head and Neck and Pediatric Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Shi ZH**: Department of Breast and Urological Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Wang AN**: Department of Breast and Urological Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Zhang CH**: Nursing Department, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Ke Y**: Department of Head and Neck and Pediatric Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n\n**Trial Design**\n\n* **Study Type**: Randomized Controlled Trial (RCT)\n* **Intervention**: Comprehensive Child Life Intervention Program (CCLIP)\n* **Control**: Standardized care\n* **Participant Selection**: Children with central nervous system (CNS) cancers undergoing radiotherapy\n* **Sample Size**: 38 participants\n* **Randomization Method**: Random number table method\n\n**Outcome Measures**\n\n* **Primary Outcome**: Reduction in medical fear among children receiving radiation treatment for CNS cancers\n* **Secondary Outcomes**:\n\t+ Anxiety\n\t+ Depression\n\t+ Radiation adherence\n\t+ Quality of life among children\n\t+ Parental satisfaction\n\n**Data Collection**\n\n* **Data Collection Methods**: Questionnaires and on-site assessments\n* **Time Points**: Four time points: day of admission (T0), first radiotherapy positioning (T1), mid-radiotherapy (T2), and postradiotherapy (T3)\n* **Data Collection Duration**: One month\n\n**Other**\n\n* **Conflict of Interest**: The authors declare no competing interests."", 'refusal': ''}}]","{'prompt_tokens': 940, 'completion_tokens': 681, 'total_tokens': 1621}"
gen-1728196455-m7soM75khJ8JLM8AeK8F,Hyperbolic,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196455,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': ""**Trial Data**\n\n**Trial ID:** EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9\n\n**Publication DOI:** 10.1002/cam4.70236\n\n**Journal:** Cancer Medicine\n\n**Publication Date:** 2024 Sep\n\n**Study Type:** Phase 3 trial\n\n**Trial Sponsor:** Regeneron Pharmaceuticals, Inc.\n\n**Intervention:**\n\n* **Cemiplimab:** 350 mg intravenously every 3 weeks\n* **Investigator's Choice Chemotherapy:** single-agent chemotherapy for up to 96 weeks\n\n**Primary Endpoint:**\n\n* **Overall Survival (OS)**\n\n**Secondary Endpoints:**\n\n* **Progression-Free Survival (PFS)**\n* **Objective Response Rate (ORR)**\n\n**Study Population:**\n\n* **Total Patients:** 608\n* **Japanese Patients:** 56 (9.2%)\n\t+ **Cemiplimab:** 29\n\t+ **Chemotherapy:** 27\n\n**Follow-up:**\n\n* **Median Duration:** 13.6 months (Japanese patients), 18.2 months (overall population)\n* **Range:** 6.0-25.3 months (Japanese patients), 6.0-38.2 months (overall population)\n\n**Efficacy Results:**\n\n* **Median OS:**\n\t+ **Cemiplimab:** 8.4 months (95% CI: 7.0-not evaluable)\n\t+ **Chemotherapy:** 9.4 months (95% CI: 5.4-14.9)\n\t+ **Hazard Ratio (HR):** 0.86 (95% CI: 0.43-1.68)\n* **Median PFS:**\n\t+ **Cemiplimab:** 4.0 months (95% CI: 1.4-8.2)\n\t+ **Chemotherapy:** 3.7 months (95% CI: 1.8-4.2)\n\t+ **HR:** 0.90 (95% CI: 0.50-1.61)\n* **ORR:**\n\t+ **Cemiplimab:** 17.2%\n\t+ **Chemotherapy:** 7.4%\n\t+ **Odds Ratio:** 2.47 (95% CI: 0.44-13.99)\n\n**Safety Results:**\n\n* **Incidence of Treatment-Emergent Adverse Events:**\n\t+ **Cemiplimab:** 79.3%\n\t+ **Chemotherapy:** 100%\n* **Grade ≥3 Adverse Events:**\n\t+ **Cemiplimab:** 37.9%\n\t+ **Chemotherapy:** 66.7%\n\n**Conflict of Interest:**\n\n* **Authors' Conflicts:** listed in the publication"", 'refusal': ''}}]","{'prompt_tokens': 2590, 'completion_tokens': 598, 'total_tokens': 3188}"
gen-1728196479-3lz9D0QbAPMqMEchxNuf,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196479,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer\n* **DOI**: 10.1186/s13058-024-01883-w\n* **PMID**: 39317942\n* **PMCID**: PMC11423510\n\n**Authors**\n\n* **First Author**: Sinn, B. V.\n* **Corresponding Author**: Sinn, B. V. (bruno.sinn@web.de)\n* **Co-Authors**:\n\t+ Sychra, K.\n\t+ Untch, M.\n\t+ Karn, T.\n\t+ van Mackelenbergh, M.\n\t+ Huober, J.\n\t+ Schmitt, W.\n\t+ Marmé, F.\n\t+ Schem, C.\n\t+ Solbach, C.\n\t+ Stickeler, E.\n\t+ Tesch, H.\n\t+ Fasching, P. A.\n\t+ Schneeweiss, A.\n\t+ Müller, V.\n\t+ Holtschmidt, J.\n\t+ Nekljudova, V.\n\t+ Loibl, S.\n\t+ Denkert, C.\n\n**Institutions**\n\n* **Department of Pathology, Charité - Universitätsmedizin Berlin**\n* **Department of Gynecology, Helios Kliniken Berlin-Buch**\n* **Department of Gynecology and Obstetrics, Goethe-University**\n* **UCT-University Cancer Center, Frankfurt-Marburg**\n* **Department of Gynecology and Obstetrics, Universitätsklinikum Schleswig-Holstein**\n* **Breast Center St. Gallen, Kantonsspital St. Gallen**\n* **Department of Gynecologic Oncology, Medical Faculty Mannheim**\n* **Mammazentrum Hamburg**\n* **Breast Center, Universitätsklinikum Frankfurt**\n* **Department of Gynecology, Uniklinik RWTH Aachen**\n* **Centrum für Hämatologie und Onkologie Bethanien**\n* **Department of Gynecology and Obstetrics, University Hospital Erlangen**\n* **Universitätsfrauenklinik Heidelberg**\n* **Department of Gynecology, Universitätsklinikum Hamburg-Eppendorf**\n* **German Breast Group, Neu-Isenburg**\n* **Department of Pathology, Philipps-University Marburg and University Hospital Marburg**\n\n**Trial Registration**\n\n* **GeparQuattro**: EudraCT 2005-001546-17\n* **GeparQuinto**: EudraCT 2006-005834-19\n* **GeparSixto**: EudraCT 2011-000553-23\n\n**Conflict of Interest**\n\n* **B. Sinn**: Employee of BioNTech SE, consultancy honoraria from Sanofi, pending patent WO2020109570A1\n* **V. Nekljudova**: GBG Forschungs GmbH employee, research grants from Abbvie, Amgen, AstraZeneca, BMS, Daiichi-Sankyo, Gilead, Molecular Health, Novartis, Pfizer and Roche\n* **T. Karn**: Patent EP18209672 pending\n* **V. Müller**: Speaker honoraria from Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, MSD, Medac, Novartis, Roche, Seagen, Onkowissen, high5 Oncology, Medscape, Gilead, Pierre Fabre and iMED Institut\n* **C. Schem**: Honoraria from Roche, Lilly, AstraZeneca, MSD Oncology, Exact Sciences and Novartis\n* **M. Untch**: Honoraria from AstraZeneca, Art tempi, Amgen, Daiji Sankyo, Lilly, Roche, Pfizer, MSD Oncology, Pierre Fabre, Sanofi-Aventis, Myriad, Seagen, Gilead, Novartis and Stemline\n* **J. Huober**: Honoraria from Lilly, Novartis, Roche, Pfizer, AstraZeneca, Seagen, Gilead and Daiichi\n* **J. Holtschmidt**: Personal fees and non-financial support from Daiichi Sankyo\n* **M. van Mackelenbergh**: Personal fees, honoraria or travel grants from Amgen, AstraZeneca, Daiichi Sankyo, Gilead, GSK, Lilly, Molecular Health, Mylan, MSD, Novartis, Pfizer, PierreFabre, Roche and Seagen\n* **S. Loibl**: GBG Forschungs GmbH employee (CEO), grants from AbbVie, AstraZeneca, Celgene, Daiichi-Sankyo, Immunomedics/Gilead, Molecular Health, Novartis, Pfizer and Roche\n* **C. Denkert**: Grants from European Commission H2020, grants from German Cancer Aid Translational Oncology, grants from German Breast Group, grants from BMBF, personal fees from Novartis, personal fees from Roche, personal fees from MSD Oncology, personal fees from Daiichi Sankyo, personal fees from AstraZeneca, from Molecular Health, grants from Myriad, personal fees from Merck, other from Sividon diagnostics\n\n**Trial Results**\n\n* **Number of Patients**: 297\n* **Subtypes**:\n\t+ Hormone receptor-positive (HR+)/human epidermal growth factor 2-negative (HER2-): 138 (46%)\n\t+ Triple-negative (TNBC): 87 (29%)\n\t+ HER2+: 72 (24%)\n* **Invasive Tumor Cells**: 70% of on-treatment biopsies\n* **Residual Tumor**: 84% of HR+/HER2-, 62% of TNBC, 51% of HER2+\n* **Pathologic Complete Response (pCR)**: 8% of patients with residual tumor, 50% of patients without invasive tumor\n* **Sensitivity**: 0.81\n* **Positive Predictive Value**: 0.92\n* **Negative Predictive Value**: 0.50\n* **Tumor-infiltrating Lymphocytes (TILs)**: Increasing TILs from baseline to on-treatment biopsy linked to higher pCR likelihood in the overall cohort (OR 1.034, 95% CI 1.013-1.056 per % increase; p = 0.001) and with a longer DFS in TNBC (HR 0.980, 95% CI 0.963-0.997 per % increase; p = 0.026)\n* **Ki-67**: Persisting or increased Ki-67 associated with lower pCR probability in the overall cohort (OR 0.957, 95% CI 0.928-0.986; p = 0.004) and shorter DFS in TNBC (HR 1.023, 95% CI 1.001-1.047; p = 0.04)', 'refusal': ''}}]","{'prompt_tokens': 2959, 'completion_tokens': 1496, 'total_tokens': 4455}"
gen-1728196554-MustFab1O1hdfTeeztKi,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196554,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Voice-Activated Cognitive Behavioral Therapy for Insomnia: A Randomized Clinical Trial\n* **Journal**: JAMA Network Open\n* **Year**: 2024\n* **Volume**: 7\n* **Issue**: 9\n* **DOI**: 10.1001/jamanetworkopen.2024.35011\n* **PMCID**: PMC11423177\n* **PMID**: 39316400\n* **ClinicalTrials.gov Identifier**: NCT05233800\n\n**Authors**\n\n* **Starling CM**: Implementation Science, Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC\n* **Greenberg D**: Media Rez, Washington, DC\n* **Lewin D**: Sleep Health and Wellness Center, Santa Barbara, California\n* **Shaw C**: Media Rez, Washington, DC\n* **Zhou ES**: Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts\n* **Lieberman D**: George Washington University, Washington, DC\n* **Chou J**: Center for Biostatistics, Informatics, and Data Science, MedStar Health Research Institute, Hyattsville, Maryland\n* **Arem H**: Implementation Science, Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC; Department of Oncology, Georgetown University, Washington DC\n\n**Study Design**\n\n* **Type**: Randomized clinical trial\n* **Duration**: 6 weeks\n* **Recruitment**: Breast cancer survivors with insomnia (Insomnia Severity Index [ISI] score >7) were recruited from advocacy and survivorship groups and an oncology clinic\n* **Eligibility criteria**:\n\t+ Female aged 18 years or older\n\t+ Completed curative treatment more than 3 months before enrollment\n\t+ Had not undergone other behavioral sleep treatments in the prior year\n\n**Intervention**\n\n* **Name**: Voice-activated cognitive behavioral therapy for insomnia (CBT-I)\n* **Type**: Voice-interactive CBT-I program delivered via smart speaker\n* **Duration**: 6 weeks\n\n**Control Group**\n\n* **Name**: Educational control\n* **Type**: Educational materials on sleep hygiene\n\n**Outcomes**\n\n* **Primary outcome**: Changes in Insomnia Severity Index (ISI) scores\n* **Secondary outcomes**:\n\t+ Sleep quality\n\t+ Wake after sleep onset\n\t+ Sleep onset latency\n\t+ Total sleep time\n\t+ Sleep efficiency\n\n**Results**\n\n* **Number of participants**: 76 (38 in each group)\n* **Completion rate**: 92.1%\n* **Mean age**: 61.2 years\n* **Mean years from diagnosis**: 9.6 years\n* **ISI score change**: -8.4 points in the intervention group vs. -2.6 points in the control group (P < 0.001)\n* **Cohen d**: 1.41 (95% CI, 0.87-1.94)\n* **Sleep diary data**:\n\t+ Sleep quality: 0.56 (95% CI, 0.39-0.74)\n\t+ Wake after sleep onset: 9.54 minutes (95% CI, 1.93-17.10 minutes)\n\t+ Sleep onset latency: 8.32 minutes (95% CI, 1.91-14.70 minutes)\n\t+ Sleep efficiency: -0.04% (95% CI, -0.07% to -0.01%)\n\t+ Total sleep time: 0.01 hours (95% CI, -0.27 to 0.29 hours)\n\n**Conflict of Interest**\n\n* **Dr. Lewin**: Received grants from the Sleep Health and Wellness Center during the conduct of the study\n* **Prof. Arem**: Received grants from the National Cancer Institute (NCI) during the conduct of the study and funding from the Maryland Department of Health and the Centers for Disease Control and Prevention outside the submitted work', 'refusal': ''}}]","{'prompt_tokens': 1079, 'completion_tokens': 843, 'total_tokens': 1922}"
gen-1728196636-huo53Wq08BrctBUc2hVY,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196636,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for this trial:\n\n**Trial Information**\n\n* **Title**: Acellular Dermal Matrix without Basement Membrane in Immediate Prepectoral Breast Reconstruction: A Randomized Controlled Trial\n* **DOI**: 10.1097/PRS.0000000000011117\n* **PMID**: 39314097\n* **Journal**: Plastic and Reconstructive Surgery\n* **Year**: 2024\n* **Month**: October\n* **Volume**: 154\n* **Issue**: 4\n* **Pages**: 649e-655e\n\n**Authors**\n\n* **Han WY** (Department of Plastic and Reconstructive Surgery, Yongin Severance Hospital, Yonsei University College of Medicine)\n* **Kim DJ** (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)\n* **Lee YS** (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)\n* **Eom JS** (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)\n* **Kim EK** (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)\n* **Han HH** (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)\n\n**Trial Design**\n\n* **Study Type**: Randomized Controlled Trial (RCT)\n* **Blinding**: Single-blind\n* **Number of Arms**: 2\n\n**Participants**\n\n* **Total Number**: 56\n* **Group 1 (ADM with basement membrane)**: 30 (53.6%)\n* **Group 2 (ADM without basement membrane)**: 26 (46.4%)\n\n**Interventions**\n\n* **Group 1**: Acellular dermal matrix (ADM) with basement membrane\n* **Group 2**: Acellular dermal matrix (ADM) without basement membrane\n\n**Outcomes**\n\n* **Primary Outcome**: Clinical and surgical characteristics, breast shape change using nipple position\n* **Secondary Outcome**: Rate of complications, rate of seromas\n\n**Results**\n\n* **No statistically significant differences** in overall rate of complications or breast shape change between the 2 groups\n* **Higher rate of seromas** in the ADM with basement membrane group (10% vs 0%, P = 0.09)\n\n**Conclusion**\n\n* **Similar surgical outcomes** between the 2 groups\n* **ADM without basement membrane** in implant-based breast reconstruction was safe, with lower tensile strength and higher elasticity.\n\n**Clinical Question/Level of Evidence**\n\n* **Therapeutic, II**', 'refusal': ''}}]","{'prompt_tokens': 615, 'completion_tokens': 569, 'total_tokens': 1184}"
gen-1728196668-Fdz23DOPwp9JsNHZWW8c,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196668,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system\n* **Journal**: Support Care Cancer\n* **Year**: 2024\n* **Volume**: 32\n* **Issue**: 10\n* **Pages**: 677\n* **DOI**: 10.1007/s00520-024-08855-y\n* **PMID**: 39304604\n\n**Authors**\n\n* **Ian R. Kleckner** (University of Maryland School of Nursing)\n* **Thilini Manuweera** (University of Maryland School of Nursing)\n* **Ping-Jung Lin** (University of Rochester Medical Center)\n* **Katherine H. Chung** (University of Maryland School of Nursing, Cornell University)\n* **Alyssa S. Kleckner** (University of Maryland School of Nursing)\n* **Jessica S. Gewandter** (University of Rochester Medical Center)\n* **Eva Culakova** (University of Rochester Medical Center)\n* **Michelle E. Tivarus** (University of Rochester Medical Center)\n* **Richard F. Dunne** (University of Rochester Medical Center)\n* **Karen P. Loh** (University of Rochester Medical Center)\n* **Supriya G. Mohile** (University of Rochester Medical Center)\n* **Sara R. Kesler** (University of Texas at Austin)\n* **Karen M. Mustian** (University of Rochester Medical Center)\n\n**Trial Registration**\n\n* **Registry**: ClinicalTrials.gov\n* **Registration Number**: NCT03021174\n* **Registration Date**: January 2017\n\n**Methods**\n\n* **Study Design**: Randomized controlled pilot study\n* **Participants**: 19 patients starting neurotoxic chemotherapy (65 ± 11 years old, 52% women; cancer type: breast, gastrointestinal, multiple myeloma)\n* **Intervention**: 12 weeks of exercise (home-based, individually tailored, moderate intensity, progressive walking, and resistance training) or active control (nutrition education)\n* **Outcome Measures**: CIPN symptoms (CIPN-20), CIPN signs (tactile sensitivity using monofilaments), physical function (leg strength), and functional connectivity in the interoceptive brain system (task-free fMRI)\n\n**Results**\n\n* **Feasibility**: 74-89% complete data across measures, 95% retention\n* **Effect Sizes**: Moderate/large beneficial effects of exercise on CIPN symptoms (CIPN-20, ES = -0.9 at mid-intervention; -0.5 at post-intervention), CIPN signs (ES = -1.0 and -0.1), and physical function (ES = 0.4 and 0.3)\n* **Functional Connectivity**: Patients with worse CIPN after neurotoxic chemotherapy had lower functional connectivity within the default mode network (R2 = 40-60%) and higher functional connectivity within the salience network (R2 = 20-40%); exercise tended to increase hypoconnectivity and decrease hyperconnectivity seen in CIPN (R2 = 12%)\n\n**Conclusion**\n\n* **Exercise during neurotoxic chemotherapy is feasible and may attenuate CIPN symptoms and signs, perhaps via changes in interoceptive brain circuitry. Future work should test for replication with larger samples.**', 'refusal': ''}}]","{'prompt_tokens': 965, 'completion_tokens': 721, 'total_tokens': 1686}"
gen-1728196708-kI3VVuPRukg6XCd5NhRh,Novita,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196708,"[{'logprobs': {'content': [], 'refusal': []}, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data extracted from the trial:\n\n**Trial Details**\n\n* **Title**: A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.\n* **Journal**: BMC Cancer\n* **Year**: 2024\n* **Volume**: 24\n* **Issue**: 1\n* **Page**: 1143\n* **DOI**: 10.1186/s12885-024-12892-5\n* **Trial Registration**: ClinicalTrials.gov: NCT04174599\n\n**Authors**\n\n* **First Author**: Zhang Q\n* **Corresponding Author**: Shao Z\n* **Authors**: Zhang Q, Wang Z, Yao W, Wang S, Zhang G, Chen J, Hou Q, Li S, Li H, Ye C, Sun T, Yang H, Chen Z, Wang Z, Liu X, Geng C, Li X, Zhang J, Zheng H, Shao Z\n\n**Trial Design**\n\n* **Type**: Randomized, open-label, active-controlled non-inferiority study\n* **Phase**: III\n* **Number of Centers**: 13\n* **Number of Patients**: 239\n* **Interventions**: F-627 (efbemalenograstim alfa) vs. filgrastim (GRAN)\n* **Dose**: F-627: 20 mg subcutaneous injection on day 3 of each cycle; filgrastim: 5 μg/kg/d subcutaneous injection starting from day 3 of each cycle\n* **Duration**: 4 cycles\n\n**Efficacy Endpoints**\n\n* **Primary Endpoint**: Duration of grade 3 or 4 neutropenia in cycle 1\n* **Secondary Endpoints**: Incidence and duration of grade 3 or 4 neutropenia and grade 4 neutropenia in cycles 1-4, ANC nadir in cycles 1-4\n\n**Results**\n\n* **Duration of Grade 3 or 4 Neutropenia in Cycle 1**: F-627: 0.68 (1.10) days; filgrastim: 0.71 (0.95) days\n* **Hodges-Lehmann Estimate of Between-Group Median Difference**: 0 day\n* **Upper Limit of One-Sided 97.5% CI**: 0 day\n* **ANC Nadir**: F-627 group was significantly higher than filgrastim group in each cycle\n\n**Safety**\n\n* **Safety Profile**: F-627 was well tolerated and as safe as standard daily filgrastim\n\n**Conclusion**\n\n* **Conclusion**: A single fixed dose of 20 mg of F-627 in each cycle was as safe and effective as a daily dose of filgrastim 5 μg/kg/d in reducing neutropenia and its complications in patients who received four cycles of EC.', 'refusal': ''}}]","{'prompt_tokens': 0, 'completion_tokens': 0, 'total_tokens': 0}"
